

4Q2023 Fact Sheet

Jeisys

Disclaimer

► This presentation represents consolidated earnings results in accordance with K-IFRS.

Please be advised that this document is provided solely for the purpose of investor convenience.

It was prepared before the completion of the external auditor's review, and therefore is subject to change

These uncertainties may cause our official results to be significantly different from the results recorded and implied in this presentation.

I. P/L (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Sales	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642	31,803	116,550	29,105	35,161	39,107	39,657	143,030
Cost of Goods sold	4,712	5,913	6,026	7,998	24,649	7,638	10,056	9,160	10,121	36,975	9,557	10,516	12,011	11,976	44,060
Ratio(%)	27%	31%	30%	33%	30%	30%	33%	32%	32%	32%	33%	30%	31%	30%	31%
Gross profit	12,546	13,326	14,378	16,397	56,647	17,696	20,715	19,482	21,682	79,575	19,548	24,646	27,096	27,680	98,970
Ratio(%)	73%	69%	70%	67%	70%	70%	67%	68%	68%	68%	67%	70%	69%	70%	69%
SG&A	7,613	7,460	8,184	9,784	33,042	9,147	11,753	11,766	12,874	45,540	11,934	14,998	16,873	18,851	62,656
Operating profit	4,933	5,865	6,194	6,613	23,604	8,549	8,962	7,716	8,808	34,035	7,614	9,648	10,223	8,829	36,314
Ratio(%)	29%	30%	30%	27%	29%	34%	29%	27%	28%	29%	26%	27%	26%	22%	25%
Net profit before income tax	-5,657	5,747	6,391	6,613	13,093	8,399	9,366	9,111	7,010	33,886	8,434	8,018	10,129	8,918	35,498
Net profit	-6,303	5,634	6,135	8,026	13,493	6,512	7,360	7,182	5,958	27,012	6,681	6,249	8,052	4,125	25,108
Ratio(%)	-37%	29%	30%	33%	17%	26%	24%	25%	19%	23%	23%	18%	21%	10%	18%
EBITDA	5,507	6,413	6,859	7,245	26,024	9,257	9,704	8,333	10,101	37,396	8,619	10,688	11,316	9,954	40,577
Ratio(%)	32%	33%	34%	30%	32%	37%	32%	29%	32%	32%	30%	30%	29%	25%	28%

Note1) 2021 1Q _ Other losses (Merger cost KRW 10,569million)

II. Sales by product portfolio (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
RF	3,974	2,994	3,837	5,881	16,686	7,058	9,355	5,923	9,065	31,402	5,841	10,044	12,451	13,372	41,708
HIFU	3,304	3,466	3,601	2,645	13,015	3,628	3,062	5,945	4,645	17,280	4,429	3,617	4,105	2,984	15,135
IPL	514	661	946	2,378	4,499	1,234	2,010	1,340	1,359	5,943	1,510	1,250	1,363	1,310	5,433
LASER	1,591	2,007	2,295	1,797	7,690	2,503	2,596	3,418	2,392	10,908	2,459	2,822	2,803	2,719	10,804
Consumables	7,260	9,413	9,573	11,069	37,315	10,237	13,120	10,740	11,424	45,521	12,754	14,304	15,318	15,363	57,739
Others	615	699	153	625	2,091	674	628	1,277	2,918	5,496	2,112	3,124	3,066	3,907	12,210
Total	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642	31,803	116,550	29,105	35,161	39,107	39,657	143,030

III. Sales Breakdown by Region (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Domestic	2,459	2,848	3,093	3,743	12,144	3,433	3,894	4,882	4,737	16,946	4,002	5,625	8,252	8,927	26,805
Overseas	14,798	16,391	17,311	20,652	69,152	21,901	26,876	23,761	27,066	99,604	25,103	29,536	30,855	30,730	116,224
Total	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642	31,803	116,550	29,105	35,161	39,107	39,657	143,030

IV. Major Device Sales

Total company (Unit : EA)	2021					2022					2023				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
LinearFirm / LinearZ	164	196	212	171	743	238	186	312	236	972	261	191	189	161	802
Cumulative Sales	1,599	1,795	2,007	2,178	-	2,416	2,602	2,914	3,150	-	3,411	3,602	3,791	3,952	-
POTENZA / DENSITY	175	99	108	192	574	300	410	197	325	1,232	167	293	310	393	1,163
Cumulative Sales	636	735	843	1,035	-	1,335	1,745	1,942	2,267	-	2,434	2,727	3,037	3,430	-

V. B/S (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2021					2022					2023				
	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31
Current assets	41,060	39,180	46,012	54,173	54,173	61,487	67,776	69,877	74,483	74,483	88,589	89,988	81,054	90,510	90,510
Cash and cash equivalents	19,582	23,263	28,668	34,291	34,291	36,394	32,274	33,627	39,583	39,583	52,017	52,593	41,436	48,830	48,830
Short-term trade Receivable	5,945	5,144	5,183	6,872	6,872	8,198	11,000	9,433	10,343	10,343	7,017	10,821	13,410	14,042	14,042
Inventories	6,190	8,171	9,679	10,578	10,578	13,234	18,329	20,423	20,380	20,380	20,328	21,522	21,373	22,617	22,617
Non-current assets	10,829	11,316	12,468	19,886	19,886	23,692	27,686	35,460	43,568	43,568	37,022	43,646	49,584	51,802	51,802
Total assets	51,889	50,496	58,481	74,059	74,059	85,178	95,462	105,337	118,052	118,052	125,611	133,634	130,638	142,313	142,313
Current liabilities	12,957	14,799	14,548	24,027	24,027	24,757	29,097	23,923	26,331	26,331	28,722	27,026	27,943	23,519	23,519
Non-current liabilities	9,936	8,678	8,569	2,379	2,379	4,040	3,995	10,485	11,579	11,579	11,494	11,022	11,263	22,544	22,544
Total liabilities	22,893	23,477	23,117	26,405	26,405	28,797	33,092	34,409	37,910	37,910	40,216	38,048	39,206	46,063	46,063
Issued capital	7,063	7,063	7,130	7,130	7,130	7,130	7,130	7,130	7,130	7,130	7,614	7,638	7,647	7,647	7,647
Total equity	28,996	27,020	35,364	47,654	47,654	56,381	62,370	70,928	80,141	80,141	85,395	95,586	91,432	96,250	96,250

Jeisys Medical Inc.

ir@jeisys.com